

Contact:

Douglas Doerfler
Chief Executive Officer
TheraMed, Inc.
(301) 517-5556

For Immediate Release

TheraMed Expands Senior Management Team in Finance and Business Development

Rockville, MD, September 5, 2001-- TheraMed, Inc. today announced that it has expanded its senior management team with the addition of Joseph Lehnen as Chief Financial Officer and Eric Richman as Vice President, Corporate Development. Prior to joining TheraMed, Mr. Lehnen was CFO for InforMax, a Maryland-based bioinformatics company, while Mr. Richman's experience includes marketing and commercialization for MedImmune, Inc.

"With the Company's recent success in initiating phase I clinical trials of ErythroMax™ and increased interest in our non-viral gene delivery platform, TheraMed is making significant progress on our corporate and product development goals. With their extensive experience in the biotechnology industry, Joe and Eric will greatly strengthen and enhance our senior management team and help us reach these goals," commented Doug Doerfler, President and CEO of TheraMed, Inc.

Mr. Doerfler continued: "Joe's extensive experience in raising private capital and launching a successful biotech IPO will be invaluable to the Company as we continue to evaluate our financing options. Eric will play an equally important role in helping TheraMed to realize the commercial potential of our proprietary targeted therapeutic products for the treatment of severe and chronic diseases."

While at InforMax, Mr. Lehnen was successful in raising \$120 million in less than two years through several rounds of venture financings and an Initial Public Offering in October, 2000. Prior to assuming his position at InforMax, Mr. Lehnen was Vice President, Investment Banking in Health Care Finance at JP Morgan & Co., where he was involved in raising capital, mergers and acquisitions and strategic advising for a variety of healthcare-oriented service providers and technology companies. Mr. Lehnen holds a Master of Public Policy degree from Harvard University, a Master of Science in Physics from Yale University, and a Bachelor of Science in Physics from Santa Clara University.

Mr. Richman has extensive experience in the development and commercialization of novel biotechnology-based therapeutics, including work at MedImmune Inc. and Healthcare Ventures. Mr. Richman was part of the founding team at MedImmune holding various administrative, financial, strategic planning and marketing positions since joining MedImmune in 1988. Most recently, Mr. Richman was Director, International Commercialization for MedImmune. Mr.

Richman was responsible for the U.S. launch of MedImmune's first commercial product and was on the launch teams for its other products. Mr. Richman received a B.S. degree in Biomedical Science from the Sophie Davis School of Biomedical Education, CUNY Medical School and a Masters of International Management from the American Graduate School of International Management.

TheraMed, Inc. is a clinical stage biotechnology company developing targeted therapeutic products to treat severe and chronic diseases, including cancer, serious infections, cardiovascular disease and genetic disorders, based on its proprietary technology that uses cells for drug and non-viral gene delivery. TheraMed is majority owned by EntreMed, Inc. For further information, please visit the TheraMed web site at <http://www.TheraMedInc.com>.

EntreMed, Inc., The Angiogenesis Company(TM), (NASDAQ: ENMD) is a clinical-stage biopharmaceutical company emphasizing antiangiogenesis therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. For further information, please visit the EntreMed web site at <http://www.entremed.com>.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

####